Journal ArticleDOI
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Jon M. Hanifin,Thurston M,Thurston M,Omoto M,Omoto M,R. Cherill,R. Cherill,Susan J. Tofte,Graeber M,Graeber M +9 more
Reads0
Chats0
TLDR
In this paper, the reliability of the EASI scoring system was evaluated by assessing inter-and intra-observer consistency, and the results indicated that the evaluators assessed the patients consistently across both study days.Abstract:
:Objective– To test the reliability of the eczema area and severity index (EASI) scoring system by assessing inter- and intra-observer consistency. Design: Training of evaluators, application, and assessment over 2 consecutive days. Setting– An academic center. Patients– Twenty adults and children with atopic dermatitis (AD); cohort 1 (10 patients ≥8 years) and cohort 2 (10 patients <8 years). Interventions– None. Main outcome measure– The EASI was used by 15 dermatologist evaluators to assess atopic dermatitis in cohort 1 and cohort 2 on 2 consecutive days. Inter- and intraobserver reliability were analyzed. Results– Overall intra-evaluator reliability of the EASI was in the fair-to-good range. Inter-evaluator reliability analyses indicated that the evaluators assessed the patients consistently across both study days. Conclusions– This study demonstrated that the EASI can be learned quickly and utilized reliably in the assessment of severity and extent of AD. There was consistency among the evaluators between consecutive days of evaluation. These results support the use of the EASI in clinical trials of therapeutic agents for AD.read more
Citations
More filters
Posted ContentDOI
A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis
TL;DR: In this paper, a model-based meta-analysis of recent clinical trials of atopic dermatitis (AD) biologics and developed a mathematical model that reproduces reported clinical efficacies for nine biological drugs (dupilumab, lebrikizumab and tralokinumab) by describing systems-level AD pathogenesis.
Book ChapterDOI
Advances in Assessing the Severity of Atopic Dermatitis
TL;DR: Some recent advances in the assessment of the severity of AD are described, which suggest easy and quick assessing severity methods are required to guide both the daily clinical and research studies.
Journal ArticleDOI
Biodegradable core-multishell nanocarrier: Topical tacrolimus delivery for treatment of dermatitis.
Moritz Radbruch,Hannah Pischon,Fang Du,Rainer Haag,Fabian Schumacher,Burkhard Kleuser,Lars Mundhenk,Achim D. Gruber +7 more
TL;DR: In this paper , the authors investigated topical delivery of tacrolimus (TAC; > 500 g/mol) by bCMS in a hydrogel on an oxazolone-induced model of dermatitis in vivo.
Calcineurin inhibitors in the treatment of allergic dermatitis Inibidores de calcineurina no tratamento das dermatoses alØrgicas
Paula Beltran,Moschione Castro +1 more
TL;DR: Calcineurin inhibitors, which are a new drug class in the treatment of allergic dermatitis, are efficient, well tolerated and have few adverse effects.
Journal ArticleDOI
General and Skin-Specific Health-Related Quality of Life in Patients With Atopic Dermatitis Before and During the COVID-19 Pandemic
Júlia Borza,MELODY BARNES,Robyn Repko Waller,Okkuziyeva Durdona Dilmurod qizi,Mirzamurodova Madina Ismatulla qizi,Zilola Abdurakhmanova Yoqubjon… +3 more
TL;DR: In this article , the authors compared health-related quality of life (HRQoL) in patients with atopic dermatitis (AD) during the COVID-19 pandemic.
References
More filters
Book
The design and analysis of clinical experiments
TL;DR: The Parallel Groups Design as mentioned in this paper is a special case of the Parallel Groups Study, and it is used to control for prognostic variables in linear regression analysis of linear regressions of linear models.
Journal ArticleDOI
Severe psoriasis--oral therapy with a new retinoid.
T. Fredriksson,Ulf Pettersson +1 more
TL;DR: Ro 10--9359 proved to be an extremely potent antipsoriatic drug and a more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment.
Journal ArticleDOI
Severity Scoring of Atopic Dermatitis: The SCORAD Index
K.U. Schallreuter,Ch. Levenig,J. Berger,J. Umbert,R.K. Winkelmann,L. Wegener,O. Correia,Olivier Chosidow,P. Saiag,S. Bastuji-Garin,J. Revuz,Jean-Claude Roujeau,R. Situ,D.R. Inman,S.E.G. Fligiel,J. Varani,R.E. Schopf,J. Dobmeyer,T. Dobmeyer,B. Morsches,K. Holubar,G.E. Piérard,O. Bongard,H. Bounameaux,P. Corcuff,J.-L. Lévêque,J. Brasch,E. Christophers,G.T. Nahass,M. Sisto,S.A. Wagner,R.U. Peter,O. Adam,T. Ruzicka,J. McGrath,N.P. Burrows,R. Russell Jones,R.A.J. Eady,S. Veraldi,G. Rizzitelli,G. Lunghi,R. Cardone,R.M. Trüeb,G. Burg,F. Wantke,G. Fleischl,M. Götz,R. Jarisch,G. Tadini,E. Ermacora,S. Cambiaghi,A. Brusasco,R. Cavalli +52 more
TL;DR: Assessment methods for atopic dermatitis are not standardized, and therapeutic studies are difficult to interpret, so consensus on these methods is needed to obtain a consensus on them.
Journal ArticleDOI
Large sample standard errors of kappa and weighted kappa.
TL;DR: The statistics kappa and weighted kappa (Cohen, 1960) were introduced to provide coefficients of agreement between two raters for nominal scales as discussed by the authors, and they were used to provide a measure of the relative seriousness of the different possible disagreements.
Related Papers (5)
Severity Scoring of Atopic Dermatitis: The SCORAD Index
K.U. Schallreuter,Ch. Levenig,J. Berger,J. Umbert,R.K. Winkelmann,L. Wegener,O. Correia,Olivier Chosidow,P. Saiag,S. Bastuji-Garin,J. Revuz,Jean-Claude Roujeau,R. Situ,D.R. Inman,S.E.G. Fligiel,J. Varani,R.E. Schopf,J. Dobmeyer,T. Dobmeyer,B. Morsches,K. Holubar,G.E. Piérard,O. Bongard,H. Bounameaux,P. Corcuff,J.-L. Lévêque,J. Brasch,E. Christophers,G.T. Nahass,M. Sisto,S.A. Wagner,R.U. Peter,O. Adam,T. Ruzicka,J. McGrath,N.P. Burrows,R. Russell Jones,R.A.J. Eady,S. Veraldi,G. Rizzitelli,G. Lunghi,R. Cardone,R.M. Trüeb,G. Burg,F. Wantke,G. Fleischl,M. Götz,R. Jarisch,G. Tadini,E. Ermacora,S. Cambiaghi,A. Brusasco,R. Cavalli +52 more